Vectors

Welcome to the Vector Purification Hub

Addressing challenges in AAV manufacturing scale-up for cost-effective gene therapies

Addressing challenges in AAV manufacturing scale-up for cost-effective gene therapies

Andrew D Tustian

Achieving robust and scalable AAV empty/full capsid separation for gene therapy

Achieving robust and scalable AAV empty/full capsid separation for gene therapy

Julio Huato, Mark Schofield

26 February 2025

Innovator Insight

Make more lentivirus and make it right the first time

Make more lentivirus and make it right the first time

Katherine Schewe

10 February 2025

Innovator Insight

Control your AAV titers with in-line UV-Vis analysis and PAT-driven UF/DF systems

Control your AAV titers with in-line UV-Vis analysis and PAT-driven UF/DF systems

Brandon Goldberg

03 February 2025

Precision in production: optimizing monitoring and quality control for high-value plasmids

Precision in production: optimizing monitoring and quality control for high-value plasmids

Oleksandr Karpenko

03 February 2025

Efficient non-viral engineering of immune cells for cell therapy using circular single-stranded DNA

Efficient non-viral engineering of immune cells for cell therapy using circular single-stranded DNA

13 January 2025

Implementing platform-based technologies to scale viral vector manufacturing consistently and efficiently

Implementing platform-based technologies to scale viral vector manufacturing consistently and efficiently

19 December 2024

Demystifying AAV affinity capture: mapping AAV affinity ligand footprints with cryo-electron microscopy

Demystifying AAV affinity capture: mapping AAV affinity ligand footprints with cryo-electron microscopy

Nathaniel Clark

13 December 2024

Navigating the complexities of AAV and lentiviral vector characterization

Navigating the complexities of AAV and lentiviral vector characterization

Susumu Uchiyama

12 December 2024

1
2
3
4
5
6
7
8
9
10
...
>
>>

Redefining AAV manufacturing: achieve exceptional performance and quality with an innovative transient cell line

Redefining AAV manufacturing: achieve exceptional performance and quality with an innovative transient cell line

Moving AAV gene therapy beyond rare disease to address large patient populations with chronic disease

Moving AAV gene therapy beyond rare disease to address large patient populations with chronic disease

Dan Oliver, Ji Hyun Lee

Transforming viral vector manufacturing with next-generation CGMP plasmids platform

Transforming viral vector manufacturing with next-generation CGMP plasmids platform

John Bowen, Brian Tomkowicz

Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing

Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing

Rob Noel, Geddy Hamblen, Christel Fenge

Efficient AAV purification: resin reuse and scalable polish method

Efficient AAV purification: resin reuse and scalable polish method

Nicolas Laroudie, Duncan Dulac

Industrialization of AAV manufacturing with Xcite® transient and stable production platforms

Industrialization of AAV manufacturing with Xcite® transient and stable production platforms

Suparna Sanyal, Peng Wang

AAV capsid analysis and quantification with chromatography and ultracentrifugation-based techniques

AAV capsid analysis and quantification with chromatography and ultracentrifugation-based techniques

Andreja Livk, Sebastijan Peljhan

27 February 2025

Avoiding scale-up pitfalls: upstream process development strategies for AAV manufacturing

Avoiding scale-up pitfalls: upstream process development strategies for AAV manufacturing

Sandy Tseng, Hugh Murray

26 February 2025

Modernizing viral clearance study strategy: regulatory updates and industry best practices

Modernizing viral clearance study strategy: regulatory updates and industry best practices

Audrey Chang, Kathleen Kenney

25 February 2025

1
2
3
4
5
6
7
8
9
10
...
>
>>